We are live on ! Find out more
MESO

Mesoblast

43 hedge funds and large institutions have $7M invested in Mesoblast in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 18 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

321% more call options, than puts

Call options by funds: $1.91M | Put options by funds: $454K

157% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 7

0.06% less ownership

Funds ownership: 0.17%0.11% (-0.06%)

2% less funds holding

Funds holding: 4443 (-1)

12% less capital invested

Capital invested by funds: $7.97M → $7M (-$970K)

14% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 7

Holders
43
Holders Change
-1
Holders Change %
-2.27%
% of All Funds
0.67%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
6
Increased
18
Reduced
7
Closed
7
Calls
$1.91M
Puts
$454K
Net Calls
+$1.46M
Net Calls Change
+$369K

MESO Hedge Fund Activity: Q2 2023 in Review

43 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Mesoblast (MESO) for Q2 2023, worth a combined $7M — down 12% from $7.97M a quarter earlier.

Sellers outnumbered buyers: 7 funds closed out of MESO and 6 opened new positions — a net loss of 1 holder — while 7 trimmed existing stakes and 18 added.

The largest buyer was Jane Street, opening a new position worth an estimated $391K. The largest seller was M&G Investment Management, exiting entirely with an estimated $1.74M sold.

  • 43 institutional investors held Mesoblast (MESO) as of Q2 2023, down from 44 in Q1 2023.
  • Funds reported $7M of Mesoblast stock for Q2 2023, down 12% quarter-over-quarter.
  • 6 funds opened new Mesoblast positions in Q2 2023 and 7 closed out, a net change of -1 holder.
  • The largest Mesoblast buyer in Q2 2023 was Jane Street, an estimated $391K added.
  • The largest Mesoblast seller in Q2 2023 was M&G Investment Management, an estimated $1.74M sold.

Based on aggregated 13F filings for Q2 2023.